New Orleans Xarelto Side Effects Attorneys – Risk of Internal Bleeding
Attorneys at The Olinde Firm are investigating claims on behalf of clients who took Xarelto and suffered uncontrollable internal bleeding. Xarelto is a one of a new class of anticoagulants (blood thinners) that is intended to reduce the risk of stroke and blood clots in patients with atrial fibrillation (A-fib), deep vein thrombosis, pulmonary embolism, or patients who have recently undergone knee or hip replacement surgery. The U.S. Food and Drug Administration (FDA) first approved Xarelto for use in 2011, and the drug has been heavily marketed as a superior alternative to Wafarin (Coumadin). Xarelto is manufactured by Bayer Healthcare and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
RISKS & SIDE EFFECTS
The most serious side effect caused by Xarelto is uncontrollable internal bleeding, which can lead to severe injury or death. Since Xarelto’s FDA approval in 2011, an increasing number of patients have reported events of uncontrollable bleeding related to their use of Xarelto. Persons using Xarelto should be aware of the following potential risks and side effects:
- Internal bleeding
- Gastrointestinal bleeding
- Cerebral/Intracranial hemorrhaging
- Nose bleeding
- Bleeding Gums
- Blood in Stool/Urine
Unlike Wafarin (Coumadin), there is no available reversal agent for Xarelto to stop its blood thinning effects, which can result in more severe and prolonged bleeding events that may lead to death. As a result, Xarelto’s risks and side effects can lead to higher occurrences of prolonged hospitalization, severe injury and even death. If you or a loved one has been hospitalized due to uncontrollable bleeding while on Xarelto, please contact an attorney at our office to discuss pursuing a recovery for your damages.
Lawyers around the country have filed lawsuits against Xarelto’s manufacturers (Bayer and Janssen Pharmaceuticals) alleging a failure to properly warn physicians and patients regarding the increased risk of uncontrollable bleeding events while on Xarelto. Additionally, plaintiffs allege the manufacturers should be held liable for marketing Xarelto without a known reversal agent to counteract its blood thinning effects. On December 4, 2014, the Judicial Panel on Multidistrict Litigation (JPML) will hear arguments regarding the transfer and consolidation of all Xarelto litigation claims before a single federal judge to coordinate discovery and pretrial proceedings in order to expedite claims filed by injured consumers.
UPDATE (August 2017):
The first two bellwether trials were tried to juries in the Eastern District of Louisiana earlier this year resulting in defense verdicts for the drug manufacturers. The third bellwether trial is set to be tried in the Southern District of Mississippi this month with the fourth bellwether trial scheduled for September 2017.
UPDATE (December 2014):
The Judicial Panel on Multidistrict Litigation (JPML) recently ordered that pending Xarelto lawsuits be transferred to the Eastern District of Louisiana and assigned to the Honorable Eldon E. Fallon for consolidation of pretrial discovery and other proceedings. This positive development will assist individuals with claims by coordinating pretrial discovery and motion practice.
FREE CASE REVIEW
If you or a loved one has been hospitalized due to uncontrollable bleeding while on Xarelto, please contact an attorney at our office to discuss obtaining a recovery for your damages.
Free Case Evaluation
Copyright © 2019 The Olinde Firm - New Orleans Attorneys. All rights reserved. Disclaimer The information contained in this website may be considered advertising under the Rules of the Supreme Judicial Court of Louisiana and is for general information purposes only. Nothing contained within this or associated pages, documents, emails, or other communications should be taken as legal advice for any individual case or situation. The information on this website is not intended to create, and communications exchanged in connection with this website are not intended to create or constitute an attorney-client relationship. Although all communications are considered confidential, we do not accept representation of clients until such time as we enter into a written agreement for such representation.